Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Chromadex Corp CS (NQ: CDXC )

1.430 +0.070 (+5.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Chromadex Corp CS

< Previous 1 2 3 Next >
Thorne Research, Inc. Loses Patent Challenge Decision, Upholding ChromaDex’s Intellectual Property Held Under Exclusive License From Dartmouth College
From ChromaDex Corporation
Via Business Wire
ChromaDex Corporation Reports Second Quarter 2022 Financial Results
From ChromaDex Corporation
Via Business Wire
ChromaDex to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
From ChromaDex Corporation
Via Business Wire
ChromaDex To Host Key Opinion Leader Webinar on the Transforming Benefits of Nicotinamide Riboside (NR)
From ChromaDex Corporation
Via Business Wire
ChromaDex to Present at American Society for Nutrition (ASN), International Society of Sports Nutrition (ISSN), and Federation of American Societies for Experimental Biology (FASEB)
From ChromaDex Corporation
Via Business Wire
ChromaDex to Present at the Oppenheimer’s 22nd Annual Consumer Growth and E-Commerce Conference
From ChromaDex Corporation
Via Business Wire
ChromaDex Signs Sinopharm Xingsha Agreement to Accelerate Cross-Border Sales of Tru Niagen® into Mainland China
From ChromaDex Corporation
Via Business Wire
ChromaDex Partners with Juvenis for Cross-Border Sales of Tru Niagen® into South Korea
From ChromaDex Corporation
Via Business Wire
ChromaDex to Present at the LD Micro Invitational
From ChromaDex Corporation
Via Business Wire
ChromaDex Announces Agreement to Launch Commercial Joint Venture in Mainland China
From ChromaDex Corporation
Via Business Wire
ChromaDex Wins International 2022 European NutraIngredients Award for Developing the Science Behind Niagen®
From ChromaDex Corporation
Via Business Wire
ChromaDex Corporation Reports First Quarter 2022 Financial Results
From ChromaDex Corporation
Via Business Wire
ChromaDex to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
From ChromaDex Corporation
Via Business Wire
ChromaDex Appoints Ann Cohen and Kristin Patrick to its Board of Directors
From ChromaDex Corporation
Via Business Wire
ChromaDex External Research Program (CERP™) Celebrates Over 250 Research Agreements With 235+ Researchers Around the World
From ChromaDex Corporation
Via Business Wire
ChromaDex Launches Tru Niagen® Immune, Further Expanding Innovative Product Portfolio
From ChromaDex Corporation
Via Business Wire
ChromaDex Announces Issuance of Additional New U.S. Continuation Patent, Further Protecting Future Innovations
From ChromaDex Corporation
Via Business Wire
ChromaDex to Report Fourth Quarter 2021 Financial Results on Wednesday, March 9, 2022
From ChromaDex Corporation
Via Business Wire
ChromaDex Announces Issuance of New U.S. Continuation Patent, Expanding Intellectual Property Portfolio for Nicotinamide Riboside
From ChromaDex Corporation
Via Business Wire
ChromaDex External Research Program (CERP™) Celebrates 100 Peer-Reviewed Published Studies on Niagen® and Other Ingredients
From ChromaDex Corporation
Via Business Wire
ChromaDex Announces Results of New Pilot Clinical Trial Showing Anti-Inflammatory Effects of Nicotinamide Riboside (NR) Supplementation
From ChromaDex Corporation
Via Business Wire
ChromaDex and Designs for Health Partner for New Product Development on Niagen®
From ChromaDex Corporation
Via Business Wire
ChromaDex Corporation Reports Third Quarter 2021 Financial Results
From ChromaDex Corporation
Via Business Wire
ChromaDex Shares Findings from First Clinical Study on Nicotinamide Riboside (NR) in Children, Highlighting Improvements for Prematurely Aging Patients with Ataxia-Telangiectasia (AT)
From ChromaDex Corporation
Via Business Wire
ChromaDex to Report Third Quarter 2021 Financial Results on Wednesday, Nov. 3, 2021
From ChromaDex Corporation
Via Business Wire
ChromaDex Comments on Jury Award Against Elysium Health and Reiterates Plans for Growth
From ChromaDex Corporation
Via Business Wire
ChromaDex Partners with Sinopharm Xingsha for Cross-Border Sales of Tru Niagen® into Mainland China
From ChromaDex Corporation
Via Business Wire
ChromaDex Shares Preclinical Research Findings and Scientific Initiations from the ChromaDex External Research Program (CERP™)
From ChromaDex Corporation.
Via Business Wire
ChromaDex Continues to Defend Strong Intellectual Property Portfolio and Plans to Appeal Judge’s Ruling in Patent Infringement Lawsuit
From ChromaDex Corporation
Via Business Wire
ChromaDex Corporation Reports Second Quarter 2021 Financial Results
From ChromaDex Corporation
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.